Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial.
Diabetes, obesity & metabolism（2023）
摘要
BI 685509 was generally well tolerated. Effects on UACR lowering merit further investigation.
更多查看译文
关键词
soluble guanylyl cyclase activator,diabetic kidney disease,pharmacokinetics,pharmacodynamics
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要